Refractory Solid Cancer Patients Unexposed to Immunotherapy

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Refractory Solid Cancer Patients Unexposed to Immunotherapy trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (1 shown)

Not Yet RecruitingPhase 2

NCT07300891

T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid…

This is a Phase 2, single-arm, multicenter study, evaluating the anti-tumor efficacy of tumor-infiltrating lymphocyte (TIL) directed tislelizumab monotherapy (a…

Location not specified72 participantsStarted 2026-08

Treatment: Tisleizumab(BGB-A317)